Table 1.

Association table of host gene polymorphisms with HBeAg seroconversion.

Gene/locus	Associated phenotype	Treatment method	Study
HLA-DOB rs2621377	Significantly associated with delayed spontaneous HBeAg seroconversion in immune-active CHB patients	Natural infection	(Liu WC. et al., 2020)
HLA-DPB2 rs3130215	Significantly associated with delayed spontaneous HBeAg seroconversion in immune-active CHB patients	Natural infection	(Liu WC. et al., 2020)
IL-28B rs12980275 rs12979860 rs8099917	Independently associated with Peg-IFNα treatment response in HBeAg-positive CHB patients of Chinese Han ethnicity	Peg-IFNα therapy	(Wu H. et al., 2015)
IL-12A rs568408	Associated with HBeAg seroconversion in ETV-treated patients	ETV therapy	(Wu J. et al., 2015)
CXCR7 rs2952665	Predictor of Peg-IFNα treatment response in HBeAg-positive CHB patients	Peg-IFNα therapy	(Luo et al., 2024)
ZHX2 rs17289471	Predictor of Peg-IFNα treatment response in HBeAg-positive CHB patients	Peg-IFNα therapy	(Hou et al., 2023)
IPS1 rs6515831 rs2464	Independently associated with HBeAg seroconversion	Natural infection	(Wang et al., 2015)
STAT4 rs7574865	Associated with HBeAg seroconversion and HBsAg loss in Peg-IFNα treated patients	Peg-IFNα therapy	(Qi et al., 2022)
TANK rs3820998	Sole independent beneficial factor for achieving HBeAg seroconversion within 3 years during NAs antiviral therapy in CHB patients	NAs therapy	(Liu WC. et al., 2020)
NTCP rs7154439	Associated with HBeAg seroconversion after 48 weeks of NAs treatment	NAs therapy	(Rybicka et al., 2019)